Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.46 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.46 |
| ▸ | WNT3A | P56704 | 1/20 | 0.46 |
| ▸ | PGK1 | P00558 | 1/20 | 0.45 |
| ▸ | RET | P07949 | 6/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | CKS1B | P61024 | 1/20 | 0.42 |
| ▸ | SKP1 | P63208 | 1/20 | 0.42 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2055259 | 0.85 | MAP4K4 (0.52) | TBK1WNT3APGK1RETPIK3CA | |
| SCHEMBL2055258 | 0.84 | APP (0.50) | TBK1GPR119WNT3APGK1RET | |
| SCHEMBL2055260 | 0.82 | MAPT (0.50) | TBK1GPR119PGK1RETPIK3CA | |
| SCHEMBL2055201 | 0.82 | NTRK1 (0.51) | APPTP53KDM4ENPC1RAB9A | |
| SCHEMBL28956351 | 0.81 | DDB1 (0.62) | DDB1CRBNGPR119WNT3ARET | |
| SCHEMBL30261848 | 0.81 | DDB1 (0.62) | DDB1CRBNGPR119WNT3ARET | |
| SCHEMBL2055256 | 0.80 | TBK1 (0.48) | TBK1WNT3APGK1RETPIK3CA | |
| SCHEMBL31166123 | 0.78 | RET (0.52) | TBK1GPR119WNT3APGK1RET | |
| SCHEMBL31239349 | 0.77 | PIK3CA (0.43) | DDB1CRBNTBK1GPR119PGK1 | |
| SCHEMBL31239336 | 0.77 | RET (0.45) | DDB1CRBNTBK1GPR119WNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8957215-B2 | Heteroaryl substituted benzothiazoles | NAVIDEA BIOPHARMACEUTICALS, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-20120207679-A1 | Novel Heteroaryl Substituted Benzothiazoles | ASTRAZENECA AB (SE) | 2012-08-16 | — | — | US | disclosed |
| US-8163928-B2 | Heteroaryl substituted benzothiazoles | ASTRAZENECA AB (SE) | 2012-04-24 | — | — | US | disclosed |
| CN-101410393-B | Novel heteroaryl substituted benzothiazoles | ASTRAZENECA AB | 2012-01-25 | — | — | CN | disclosed |
| CN-101410393-A | Novel heteroaryl substituted benzothiazoles | ASTRAZENECA AB (SE) | 2009-04-15 | — | — | CN | disclosed |
| US-20090028787-A1 | Novel Heteroaryl Substituted Benzothiazoles | NAVIDEA BIOPHARMACEUTICALS, INC. | 2009-01-29 | — | — | US | disclosed |
| EP-1981883-A1 | NOVEL HETEROARYL SUBSTITUTED BENZOTHIAZOLES | AstraZeneca AB (SE) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007086800-A1 | NOVEL HETEROARYL SUBSTITUTED BENZOTHIAZOLES | ASTRAZENECA AB (SE) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090028787-A1 | Novel Heteroaryl Substituted Benzothiazoles | APP, MAPT, PSEN1 | DDB1 2085/4885CRBN 1113/4885TBK1 731/4885 |
| US-20120207679-A1 | Novel Heteroaryl Substituted Benzothiazoles | MAPT, APP, PSEN1 | DDB1 2340/4885CRBN 1891/4885TBK1 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.